Dermata Therapeutics Inc (DRMA) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Dermata Therapeutics Inc (DRMA) has a cash flow conversion efficiency ratio of -0.214x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-1.33 Million) by net assets ($6.22 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See Dermata Therapeutics Inc (DRMA) net asset quality to measure how much of total assets are equity-financed.
Dermata Therapeutics Inc - Cash Flow Conversion Efficiency Trend (2019–2025)
This chart illustrates how Dermata Therapeutics Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore Dermata Therapeutics Inc cash flow to debt ratio to assess how comfortably operating cash covers total debt obligations.
Dermata Therapeutics Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Dermata Therapeutics Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Sonetel AB
ST:SONE
|
0.069x |
|
Preecha Group Public Company Limited
BK:PRECHA
|
-0.044x |
|
Nichols
LSE:NICL
|
0.010x |
|
Big Tree Cloud Holdings Limited Ordinary Shares
NASDAQ:DSY
|
-0.225x |
|
Grand Foundry Limited
NSE:GFSTEELS
|
0.083x |
|
THREED CAPITAL INC.
F:B5K3
|
N/A |
|
Strategic Energy Resources Limited
F:EB8
|
-0.012x |
|
Erika Carmel Ltd
TA:BCUR
|
0.113x |
Annual Cash Flow Conversion Efficiency for Dermata Therapeutics Inc (2019–2025)
The table below shows the annual cash flow conversion efficiency of Dermata Therapeutics Inc from 2019 to 2025. For the full company profile with market capitalisation and key ratios, see Dermata Therapeutics Inc (DRMA) total market value.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $6.22 Billion | $-7.76 Billion | -1.247x | +82.57% |
| 2024-12-31 | $1.56 Million | $-11.16 Million | -7.151x | -609.06% |
| 2023-12-31 | $6.36 Million | $-6.41 Million | -1.008x | +31.26% |
| 2022-12-31 | $6.02 Million | $-8.83 Million | -1.467x | -160.43% |
| 2021-12-31 | $10.11 Million | $-5.69 Million | -0.563x | -144.44% |
| 2020-12-31 | $-3.18 Million | $-4.03 Million | 1.268x | -93.21% |
| 2019-12-31 | $-210.16K | $-3.92 Million | 18.663x | -- |
About Dermata Therapeutics Inc
Dermata Therapeutics, Inc. engages in the development and distribution of over-the-counter pharmaceutical dermatology-focused products in the United States. The company develops direct-to-consumer skincare products, including foundation treatment products for skin renewal and clearing treatment products for the treatment of acne under the Tome brand. Dermata Therapeutics, Inc. was incorporated in… Read more